NCT03988582 2020-06-11Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated MalignanciesMemorial Sloan Kettering Cancer CenterPhase 2 Withdrawn